Pharma: Page 35
-
Q&A
'Nobel Prize of pharma' helps put Huma's digital health platform on the global map
The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.
By Kim Ribbink • June 23, 2022 -
#DIA2022: Building 'guardrails' in the FDA's accelerated approval program
Regulatory experts weigh in on ways to enhance the controversial drug approval approach.
By Karissa Waddick • June 21, 2022 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
The public health sleuth
In her decades-long career, Mary Pittman, CEO of the Public Health Institute, has seen — and helped solve — one public health mystery after another.
By Alexandra Pecci • June 21, 2022 -
#DIA2022: How the industry's top regulator views the future of healthcare
In the evolution of healthcare, data is the linchpin to making drug development more efficient.
By Michael Gibney • June 21, 2022 -
A patient-funded ALS drug offers hope where few treatments exist
Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.
By Kelly Bilodeau • June 15, 2022 -
TikTok tutorial: How pharma can embrace the video platform's educational potential
Ogilvy Health’s director of social strategy, Katie Ferrigno, busts myths and provides tips on how biopharmas can take advantage of TikTok’s unique features to connect with patients.
By Karissa Waddick • June 15, 2022 -
Podcast
Woman of the Week: Tango Therapeutics' Dr. Barbara Weber
A pioneer in genetic medicine, Dr. Barbara Weber continues to push the envelope to expand the reach of therapies based on genetic targeting.
By Taren Grom • June 14, 2022 -
Profile
Buoyed by COVID-19 shot, J&J's vaccines head sees a new golden age approaching
Janssen’s goal to have ‘a vaccine for the world’ is part of what drew Penny Heaton to the company and its work.
By Alexandra Pecci • June 14, 2022 -
Making Moves
Making moves: Civica, Astellas, Inozyme and more announce key new hires
The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics.
By Karissa Waddick • June 13, 2022 -
Sponsored by GoodRx
How to boost utilization of your copay program
Give your copay program the gift of awareness. GoodRx provides a better way to effective programs
June 13, 2022 -
Q&A
A combo of precision meds and diagnostics could disrupt mental healthcare
HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.
By Kelly Bilodeau • June 8, 2022 -
Podcast
Woman of the Week: Janssen’s Najat Khan
Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.
By Taren Grom • June 8, 2022 -
As cancer innovations thrive, patient access is the next piece of the puzzle
Why enhanced clinical trials and diagnostics are keys to boosting patient access to cancer care.
By Michael Gibney • June 8, 2022 -
Pharma giants take on Appalachian cancer rates in newest screening initiative
AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.
By Karissa Waddick • June 7, 2022 -
Q&A // First 90 Days
First 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
By Taren Grom • June 6, 2022 -
How to build a cancer pipeline: Big Pharma oncology heads on driving science forward
Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.
By Michael Gibney • June 6, 2022 -
Aduhelm's Medicare woes leave questions about lofty premiums
A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.
By Kelly Bilodeau • June 2, 2022 -
Profile
Flagship's creative approach to finding the next big idea in biopharma
Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.
By Alexandra Pecci • June 1, 2022 -
Cell and gene therapy advances coming fast and furious
A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.
By Kelly Bilodeau • June 1, 2022 -
SIGA prepares to kick production for monkeypox treatment into high gear
‘We’re not bored,’ the company’s science chief says as SIGA Technologies looks to ramp up supplies of its therapeutic.
By Meagan Parrish • May 31, 2022 -
Q&A // First 90 Days
First 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
By Kim Ribbink • May 31, 2022 -
PBMs under fire for drug prices defend their worth
A new Senate bill is putting PBMs in the crosshairs of lawmakers — but they argue that they're more than just middlemen.
By Michael Gibney • May 26, 2022 -
Making Moves
Making moves: Inovio, Veru, MindMed and more announce key new hires
The latest career moves in the biopharma industry from Veru, MindMed, Horizon Therapeutics and Inovio.
By Karissa Waddick • May 25, 2022 -
Podcast
Woman of the Week: Ferring Pharmaceutical's Araz Raoof
Growing up in Iraqi Kurdistan, Raoof says a 'lethal combination' of books and strong women paved her way into STEM.
By Taren Grom • May 25, 2022 -
Pharmas can be 'more than medicine' by focusing on preventative care
Why pharma companies are changing their tack to become more than the products they sell.
By Michael Gibney • May 24, 2022